Shares of Braveheart Investment (LON: BRH) are rallying after the company provided an update on progress to develop a COVID-19 test that Paraytec Limited is working on in conjunction with the University of Sheffield.
Braveheart said that in clinical analyses, over 120 patient nasopharyngeal swab samples have been successfully analysed using the Paraytec test, achieving 94% sensitivity and 100% specificity.
A key difference in the Paraytec test is its ability to distinguish between intact viral particles and residual RNA fragments, a cause for concern amongst some people as RNA fragments are present in the nose and throat and can yield a positive PCR test result for several weeks after peak viral load has passed.
Sponsored content
Ready to put what you’ve learned into practice?
Try IG’s platform with £10,000 in virtual funds and practise trading
without putting your own money at risk.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Sponsored content
Learn the markets with IG Academy
Build your knowledge with IG Academy educational content, then use a
demo account to practise what you’ve learned on the IG platform.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Sponsored content
See how trading works before risking real money
IG’s demo gives you access to thousands of markets and £10,000 in
virtual funds, so you can explore the platform and test your ideas first.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Sponsored content
Turn trading theory into practical experience
Learn with IG Academy, explore charts and market tools, and practise
strategies in a simulated trading environment before going live.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Sponsored content
Ready to take your learning further?
IG combines market education, analysis and an established trading platform,
giving you the tools to keep learning as you develop your trading skills.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
“The Paraytec team has developed a new method to determine the proportion of RNA that is encapsulated within viral particles in clinical samples, compared with total RNA that includes non-infectious RNA fragments,” Braveheart said in a statement.
“This method will allow the team to refine its analysis of test performance for operational sensitivity,” the company added.
Braveheart is now in the process of engaging specialist consultants to identify and target an extensive range of commercial partners for the Paraytec technology.
Sponsored
Source: IG
Braveheart Investment’s share price has climbed 11.63% to 48p so far in today’s session, reaching highs of 53p earlier in the day.
Should you invest in Braveheart Investment shares?
Braveheart Investment shares are traded on the London stock exchange’s AIM market (the alternative investment market), which is the submarket specifically for smaller companies. AIM stocks are attractive to investors as they have tax advantages and smaller companies have the potential to benefit from rapid growth. But are Braveheart Investment shares the best buy? Our stock market analysts regularly review the market and share their picks for high growth companies
Sam ist Händler und leitender Aktienmarkt-Analyst auf AskTraders. Nachdem er seine Karriere auf dem Devisenmarkt begonnen hat, konzentriert sich Sam nun auf Aktien, insbesondere auf Basiskonsumgüter.
